Heart failure

Ohio State First in Country to Use New Treatment for Heart Failure Patients


The system consists of a bedside stimulation console and a minimally invasive catheter, which is placed via a vein in the neck and through the heart. It is found in the pulmonary artery to stimulate a nerve at the back of the heart. Early studies have shown that nerve stimulation can increase the strength of the heartbeat to pump blood more efficiently throughout the body without significantly increasing the heart rate.

“Currently, drugs are the primary treatment for acute decompensated heart failure, but many have side effects that may limit benefits, especially for sicker or more complex patients. The options for treating ADHF have not evolved as quickly, despite a significant and continuing need for proven treatments. What is really new about this system is that it treats both the underlying problem and the symptoms of ADHF, ”said Dr Sitaramesh Emani, director of clinical research on ADHF. heart failure at the Ohio State Wexner Medical Center and associate professor of cardiovascular medicine at the College of Medicine. .

ADHF is the sudden or gradual onset of signs or symptoms of heart failure. These include severe shortness of breath, rapid weight gain, and fluid buildup in the lungs and around the body. The condition requires medical attention, resulting in emergency room visits, hospitalization, and readmission.

Robert Dye, 65, of Columbus decided to participate in the clinical trial after struggling with shortness of breath and poor circulation. Walking from the bedroom to the living room would leave him breathless, and he would have to get up several times a night to sit on the edge of the bed to catch his breath since he couldn’t lie on his back.

“I feel 100% better and I feel like I have a new life. My color has returned, I am no longer short of breath and my legs and arms are no longer cold, ”he said. “It’s a 180 degree turnaround.

Emani, who is on the scientific advisory board of the system’s manufacturer, Cardionomics, helped develop the system’s protocol and participated in an initial feasibility study. The clinical trial is expected to continue at Ohio State Wexner Medical Center over the next two years.

According to the Centers for Disease Control & Prevention, approximately 6.2 million adults in the United States have heart failure.

###

Media Contact: Amy Colgan, Wexner Medical Center Public Affairs and Media Relations, 614-425-0424 or [email protected]


Leave a Reply

Your email address will not be published.